Small Animal Internal Medicine Resident The Ohio State University Dublin, OH, United States
Abstract: Background – Serum uremic toxin concentrations (UT) markedly increase in cats with chronic kidney disease (CKD) and can have deleterious consequences. Porus® One is an oral adsorbent that binds UT precursors in the gut. Objectives/Hypothesis – Assess the effect of Porus® One on UT in cats with CKD. Animals – 14 purpose-bred cats (13 IRIS Stage 2, 1 IRIS Stage 3). Methods – Prospective cross-sectional study utilizing cats with remnant kidney model-induced CKD. Cats were treated with standard of care (Days –56 to 0) and then 500 mg Porus® One PO q24h (Days 0 to 56) in food. Serum concentrations of indoxyl sulfate (IDS) and p-cresyl sulfate (pCS) were measured (Days -56, -28, 0, 28, and 56) by LC/MS/MS. Doppler blood pressure (BP), complete blood cell count, biochemistry, urinalysis, and urine protein: creatinine ratio were measured (Days -56, 0, and 56). UT and clinicopathologic variables were compared before and after administration of Porus® One. Results – Averaged serum IDS and pCS concentrations were significantly decreased after administering Porus® One relative to averaged baseline concentrations (Table 1). Concentrations of ICS and pCS at Day 28 (but not Day 56) significantly decreased relative to Day 0. BP significantly decreased (p = 0.03), and serum bicarbonate concentrations significantly increased (p = 0.03) after administering Porus® One. Serum creatinine concentrations were significantly increased at Day 56 relative to Day -56 (p = 0.002) but not relative to Day 0. Conclusions and clinical importance – Porus® One decreased UT despite mild progression of disease.
